What question did this study set out to answer?

To compare overall survival between nivolumab and docetaxel in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC).

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

To compare overall survival between nivolumab and docetaxel in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC).
Randomized trial involving patients who progressed during or after platinum-based chemotherapy.
Comparison of overall survival rates between nivolumab and docetaxel.
Nivolumab resulted in longer overall survival compared to docetaxel.

No takes yet. Share an insight, caveat, or question.

Randomized trial compares overall survival in advanced nonsquamous lung cancer, implying nivolumab may be more effective.

Borghaei et al. (2015) studied this question.

View Full Paper

Ask AI

Bookmark